Tamarly Intelligence
Company · Private

AI3 Bio, Inc.

Share this pageLinkedInXEmail
Key figures
SEC number
2019875

Source: SEC EDGAR filings and company facts; checked 6 Nov 2026

About

Preclinical biotechnology company in Watertown, Massachusetts developing treatments for autoimmune disease by eliminating disease-causing Th17 cells in the body.

Rounds and raises
4 Nov 2026
Form D: $48M sold of $48M offered, Biotechnology SEC
4 Nov 2026
Form D: $0M sold, Biotechnology SEC
20 Oct 2025
Form D: $17M sold of $17M offered, Pharmaceuticals SEC

Source: SEC EDGAR Form D and the linked articles. All raises this week

Latest filings
4 Nov 2026
D D
4 Nov 2026
D D
20 Oct 2025
D D
23 Apr 2024
D D

Source: SEC EDGAR

Questions and answers

What does AI3 Bio, Inc. do?
Preclinical biotechnology company in Watertown, Massachusetts developing treatments for autoimmune disease by eliminating disease-causing Th17 cells in the body.
Free, with no account

The rest of this page is free to read: 12 quarters of figures, every filing and document, earnings call transcripts, holders and ownership changes, the Brain's cards and graph, exports to Excel.

Explore for freeSign in

Research from public records, not investment advice. Tamarly holds no investment positions. By reading these pages you accept the Terms of Use; figures can be late or wrong, so check the linked source before relying on one. Terms and policies.